SPOTLIGHT -
Sumanta K. Pal, MD, FASCO, on CONTACT-03 Trial and Investigating Targeted Therapy, Immunotherapy for Patients with RCC
Pal detailed the plan for the CONTACT-03 study and what the research team hopes to see with the data.
Sumanta K. Pal, MD, FASCO, on Moving Forward with Cabozantinib as Treatment for Patients with RCC
Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.
Sumanta K. Pal, MD, FASCO, on Tolerability of Lenvatinib and Everolimus to Treat Patients With RCC
Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.
Sumanta K. Pal, MD, FASCO, on Cabozantinib Efficacy in SWOG 1500 for Papillary RCC
Pal discussed findings from the SWOG 1500 trial investigating sunitinib versus either cabozantinib, crizotinib, or savolitinib to treat patients with metastatic papillary RCC.
ctDNA Reveals Genomic Differences of mRCC During First-, Second-Line Therapy
This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.
Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases
Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.
Metastatic Adrenocortical Carcinoma With a Prolonged Response to Mitotane
Adrenocortical carcinoma is a rare disease, with an annual incidence rate ranging from 0.5 to 2.0 cases per million individuals.
